Serum Levels of Soluble Fas in Patients with Multinodular Goiter

REFERENCES

• Andrikoula M., Tsatsoulis A. The role of Fas-mediated apoptosis in thyroid diseases. Eur. J. Endocrinol. 2001; 144: 561–568
   PubMed Web of Science ®Google Scholar
• Andrikoula M., Vartholomatos G., Tsangaris G., Bafa M., Tzortzatou-Stathopoulou F., Tsatsoulis A. Fas and Bcl-2 protein expression in thyrocytes of patients with nodular goiter. Eur. J. Endocrinol. 2001; 145: 403–407
   PubMedGoogle Scholar
• Behrmann I., Walczak H., Krammer P. H. Structure of the human APO-1 gene. Eur J. Immunol. 1994; 24: 3057–3062
   PubMedGoogle Scholar
• Bossowski A., Czarnocka B., Bardadin K., Stasiak-Barmuta A., Urban M., Dadan J., Ratomski K., Bossowksa A. Identification of apoptotic proteins in thyroid gland from patients with Graves' disease and Hashimoto's thyroiditis. Autoimmunity 2008; 41: 163–173
   PubMed Web of Science ®Google Scholar
• Chen S., Fazle Akbar S. M., Zhen Z., Luo Y., Deng L., Huang H., Chen L., Li W. Analysis of the expression of Fas, FasL and Bcl-2 in the pathogenesis of autoimmune thyroid disorders. Cell. Mol. Immunol. 2004; 1: 224–228
   PubMed Web of Science ®Google Scholar
• Cheng J., Zhou T., Liu C., Shapiro J. P., Brauer M. J., Kiefer M. C., Barr P. J., Mountz J. D. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759–1762
   PubMed Web of Science ®Google Scholar
• Feldkamp J., Pascher E., Perniok A., Scherbaum W. A. Fas-mediated apoptosis is inhibited by TSH and iodine in moderate concentrations in primary human thyrocytes in vitro. Horm. Metab. Res. 1999; 31: 355–358
   Google Scholar
• Feldkamp J., Pascher E., Schott M., Goretzki P., Seissler J., Scherbaum W. A. Soluble Fas is increased in hyperthyroidism independent of the underlying thyroid disease. J. Clin. Endocrinol. Metab. 2001; 86: 4250–4253
   PubMed Web of Science ®Google Scholar
• Fountoulakis S., Vartholomatos G., Kolaitis N., Frillingos S., Philippou G., Tsatsoulis A. Differential expression of Fas system apoptotic molecules in peripheral lymphocytes from patients with Graves' disease and Hashimoto's thyroiditis. Eur. J. Endocrinol. 2008; 158: 853–859
   PubMed Web of Science ®Google Scholar
• Furuya Y., Fuse H., Masai M. Serum soluble Fas level for detection and staging of prostate cancer. Anticancer Res. 2001; 21: 3595–3598
   Google Scholar
• Furuya Y., Nagakawa O., Fuse H. Prognostic significance of serum soluble Fas level and its change during regression and progression of advanced prostate cancer. Endocr. J. 2003; 50: 629–633
   Google Scholar
• Giordano C., Richiusa P., Bagnasco M., Pizzolanti G., Di Blasi F., Sbriglia M. S., Mattina A., Pesce G., Montagna P., Capone F., Misiano G., Scorsone A., Pugliese A., Galluzzo A. Differential regulation of Fas-mediated apoptosis in both thyrocyte and lymphocyte cellular compartments correlates with opposite phenotypic manifestations of autoimmune thyroid disease. Thyroid 2001; 11: 233–244
   PubMed Web of Science ®Google Scholar
• Giordano C., Stassi G., De Maria R., Todaro M., Richiusa P., Papoff G., Ruberti G., Bagnasco M., Testi R., Galluzzo A. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 1997; 275: 960–963
   PubMed Web of Science ®Google Scholar
• Hammond L. J., Lowdell M. W., Cerrano P. G., Goode A. W., Botazzo G. F., Mirakian R. Analysis of apoptosis in relation to tissue destruction associated with Hashimoto's autoimmune thyroiditis. J. Pathol. 1997; 182: 138–144
   PubMedGoogle Scholar
• Hefler L., Mayerhofer K., Nardi A., Reinthaller A., Kainz C., Tempfer C. Serum soluble Fas levels in ovarian cancer. Obstet. Gynecol 2000; 96: 65–69
   PubMed Web of Science ®Google Scholar
• Hiromatsu Y., Bednarczuk T., Soyejima E., Miyake I., Yang D., Fukazawa H., Nonaka K. Increased serum soluble Fas in patients with Graves' disease. Thyroid 1999; 9: 341–345
   PubMed Web of Science ®Google Scholar
• Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 2230–2243
   Google Scholar
• Jodo S., Kobayashi S., Kayagaki N., Ogura N., Feng Y., Amasaki Y., Fujisaku A., Azuma M., Okumura K., Koike T. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in Systemic Lupus Erythematosus (SLE) and other autoimmune diseases. Clin. Exp. Immunol. 1997; 107: 89–95
   Google Scholar
• Jodo S., Kobayashi S., Nakajima Y., Matsunaga T., Nakayama N., Ogura N., Kayagaki N., Okumura K., Koike T. Elevated serum levels of soluble Fas/APO-1(CD95) in patients with hepatocellular carcinoma. Clin. Exp. Immunol. 1998; 112: 166–171
   PubMed Web of Science ®Google Scholar
• Kikuchi S., Hiraide H., Tamakuma S., Yamamoto M. Expression of wild-type p53 tumor suppressor gene and its possible involvement in the apoptosis of thyroid tumors. Surg. Today 1997; 27: 226–233
   Google Scholar
• Konno R., Takano T., Sato S., Yajima A. Serum soluble Fas level as a prognostic factor in patients with gynecological malignancies. Clin. Cancer Res. 2000; 6: 3576–3580
   PubMed Web of Science ®Google Scholar
• Kotani T., Aratake Y., Hirai K., Fukazawa Y., Sato H., Ohtaki S. Apoptosis in thyroid tissue from patients with Hashimoto's thyroiditis. Autoimmunity 1995; 20: 231–236
   PubMed Web of Science ®Google Scholar
• Kushlinskii N. E., Britvin T. A., Abbasova S. G., Perevoshchikov A. G., Prorokov V. V., Kostanyan I. A., Knysh V. I., Lipkin V. M. Serum Fas antigen in the serum of patients with colon cancer. Bull. Exp. Biol. Med. 2001; 131: 361–363
   Google Scholar
• Kushlinskii N. E., Britvin T. A., Polyakova G. A., Abbasova S. G., Baronin A. A., Bogatyrev O. P., Kalinin A. P., Lipkin V. M. Serum Fas antigen (sFas) in the serum of patients with adrenal tumours. Bull. Exp. Biol. Med. 2001; 132: 990–992
   Google Scholar
• Liu C., Cheng J., Mountz J. D. Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. Biochem. J. 1995; 310: 957–963
   PubMed Web of Science ®Google Scholar
• Mizutani Y., Yoshida O., Bonavida B. Prognostic significance of soluble Fas in the serum of patients with bladder cancer. J. Urol. 1998; 160: 571–576
   Google Scholar
• Moore D., Ohene-Fianko D., Garcia B., Chakrabarti S. Apoptosis in thyroid neoplasms: relationship with p53 and bcl-2 expression. Histopathology 1998; 32: 35–42
   Google Scholar
• Nonomura N., Nishimura K., Ono Y., Fukui T., Harada Y., Takaha N., Takahara S., Ohtsuka K., Hashimoto M. Serum levels of soluble Fas in patients with Graves' ophtalmopathy. Br. J. Ophthalmol. 2000; 84: 103–106
   Google Scholar
• Okuyama A. Soluble Fas in serum from patients with renal cell carcinoma. Urol. 2000; 55: 151–155
   Google Scholar
• Seishima M., Takemura M., Saito K., Sano H., Minatoguchi S., Fujiwara H., Hachiya T., Noma A. Highly sensitive ELISA for soluble Fas in serum: increased soluble Fas in the elderly. Clin. Chem. 1996; 42: 1911–1914
   Google Scholar
• Shimaoka Y., Hidaka Y., Okumura M., Takeoka K., Tada H., Amino N. Serum concentration of soluble Fas in patients with autoimmune thyroid diseases. Thyroid 1998; 8: 43–47
   Google Scholar
• Sreelekha T. T., Pradeep V. M., Vijayalakshmi K., Belthazar A., Chellam V. G., Nair B., Pillai M. R. In situ apoptosis in the thyroid. Thyroid 2000; 10: 117–122
   Google Scholar
• Suda T., Okazaki T., Naito Y., Yokota T., Arai N., Ozaki S., Nakao K., Nagata S. Expression of the Fas Ligand in cells of T cell lineage. J. Immunol. 1995; 154: 3806–3813
   PubMed Web of Science ®Google Scholar
• Tamura M, Kimura H, Koji T., Tominaga T, Ashizawa K., Kiriyama T, Yokoyama N., Yoshimura T., Eguchi K., Nakane P. K., Nagataki S. Role of apoptosis of thyrocytes in a rat model of goiter. A possible involvement of Fas system. Endocrinol 1998; 139: 3646–3653
   Google Scholar
• Tanimoto C., Hirakawa S., Kawasaki H., Hayawaka N., Ota H. Apoptosis in thyroid diseases: a histochemical study. Endocr. J. 1995; 42: 193–201
   PubMedGoogle Scholar
• Wang C. Y., Zhong W. B., Chang T. C., Tsai Y. F. Circulating soluble Fas ligand correlates with disease activity in Graves' hyperthyroidism. Metabolism 2002; 51: 769–773
   PubMed Web of Science ®Google Scholar
• Watanabe F. R., Brannan C. L., Itoh N., Yonehara S., Copeland N. G., Jenkins N. A., Nagata S. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol. 1992; 148: 1274–1279
   Google Scholar